The aim of our study was to clarify the role of the CCR5delta32 allele in HCV-related outcomes, by performing comprehensive genotyping of CCR5 in a large and diverse population of anti-HCV-positive persons and by correlating findings with the degree of liver inflammation, fibrosis stage, fibrosis progression rate, steatosis, HCV spontaneous clearance and response to IFN-alpha-based therapy. The gene discussed is CCR5; the disease is fibrosis.